We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Celadon Pharmaceuticals Plc | LSE:CEL | London | Ordinary Share | GB00BDQYGP38 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
1.50 | 2.52% | 61.00 | 57.00 | 65.00 | 61.00 | 59.50 | 59.50 | 12,246 | 14:00:11 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Investment Advice | 149k | -7.14M | -0.1082 | -5.64 | 39.26M |
RNS No 6148h CELSIS INTERNATIONAL PLC Date of Disclosure..18 MAY 1998.......... DISCLOSURE UNDER RULES 8.1(a), 8.1(b)(i) and 8.3 OF THE CITY CODE ON TAKE-OVERS AND MERGERS Date of dealing..15 MAY 1998........ Dealing in...CELSIS INTERNATIONAL PLC......................(name of company) (1) Class of securities (eg ordinary shares)...ORD 1P..................... (2) Amount bought Amount sold Price per unit 29,768 - 0.44 (3) Resultant total of the same class owned or controlled (and percentage of class)....1,194,030............................. (1.19%) (4) Party making disclosure..HENDERSON INVESTORS LTD AND ITS FELLOW SUBSIDIARIES (INCLUDING AMP ASSET MANAGEMENT LTD) (5) EITHER (a) Name of purchaser/vendor (Note 1)............................. OR (b) if dealing for discretionary client(s), name of fund management organisation ...............AMP ASSET MANAGEMENT LTD........................................ (6) Reason for disclosure (Note 2) (a) associate of (i) offeror (Note 3) NO (ii) offeree company NO Specify which category or categories of associate (1-8 overleaf)....N/A........ If category (8), explain.........N/A............................................ ................................................................................ (b) Rule 8.3 (ie disclosure because of ownership or control of 1% or more of the class of relevant securities dealt in) YES Signed, for and on behalf of the party named in (4) above......N/A.............. (Also print name of signatory)...A G VERNEY..................................... Telephone and extension number...0181 989 0863.................................. Note 1. Specify owner, not nominee or vehicle company. If relevant, also identify controller of owner, eg where an owner normally acts on instructions of a controller. Note 2. Disclosure might be made for more than one reason; if so, state all reasons. Note 3. Specify which offeror if there is more than one. Note 4. When an arrangement exists with any offeror, with the offeree company or with an associate of any offeror or of the offeree company in relation to relevant securities, details of such arrangement must be disclosed, as required by Note 6 on Rule 8............................................................ ............................................................................... ............................................................................... For full details of disclosure requirements, see Rule 8 of the Code. If in doubt, contact the Panel on Take-overs and Mergers, Tel. No: 0171-382 9026. END DCCFLGMKZRMLRMM
1 Year Celadon Pharmaceuticals Chart |
1 Month Celadon Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions